EVIDENCE LIBRARY
Lorazepam changed neutral auditory ERPs without significant anxiety-scale improvement
A small experimental component separated a neural signal from reported anxiety and other auditory outcomes.
A small experimental component separated a neural signal from reported anxiety and other auditory outcomes.
The selective response
Within a broader study of serotonin-transporter variation and auditory processing, acute lorazepam reduced neutral-stimulus event-related potential amplitudes in participants with high trait anxiety. The treatment did not significantly change the reported anxiety scales or the tested fearful and angry mismatch-negativity measures.
The paper’s broader mechanistic conclusions should therefore retain this selective pharmacological finding rather than claiming normalization of every anxiety-related measure.
A biomarker change is not automatically symptom relief
The lorazepam component was small and used specific auditory stimuli. Electrophysiological amplitude does not directly establish improved daily functioning, clinical remission, or impairment. Stimulus characteristics and statistical uncertainty limit interpretation.
For evidence review, state the changed endpoint and the unchanged endpoints together. The study supports a possible effect on baseline auditory responsiveness while leaving broader clinical significance unresolved. It cannot determine an individual’s anxiety or capacity from a research ERP pattern.
Source paper
Original analysis of the supplied journal article, identified as PMC7064530.